Australia markets open in 2 hours 53 minutes

Scinai Immunotherapeutics Ltd. (SCNI)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.4661-0.0029 (-0.62%)
At close: 04:00PM EDT
0.4750 +0.01 (+1.91%)
After hours: 05:40PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.71M
Enterprise value 16.15M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.59
Enterprise value/revenue N/A
Enterprise value/EBITDA -1.57

Trading information

Stock price history

Beta (5Y monthly) 2.45
52-week change 3-76.24%
S&P500 52-week change 322.38%
52-week high 32.2700
52-week low 30.4310
50-day moving average 30.4871
200-day moving average 30.7548

Share statistics

Avg vol (3-month) 327k
Avg vol (10-day) 311.3k
Shares outstanding 55.81M
Implied shares outstanding 64.73M
Float 81.02B
% held by insiders 124.21%
% held by institutions 110.63%
Shares short (15 Apr 2024) 422.54k
Short ratio (15 Apr 2024) 40.84
Short % of float (15 Apr 2024) 40.57%
Short % of shares outstanding (15 Apr 2024) 40.52%
Shares short (prior month 15 Mar 2024) 412.74k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 325 Nov 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-35.71%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -10.29M
Net income avi to common (ttm)-9.29M
Diluted EPS (ttm)-4.4000
Quarterly earnings growth (yoy)216.30%

Balance sheet

Total cash (mrq)6.36M
Total cash per share (mrq)0
Total debt (mrq)19.81M
Total debt/equity (mrq)N/A
Current ratio (mrq)4.36
Book value per share (mrq)-0.62

Cash flow statement

Operating cash flow (ttm)-8.75M
Levered free cash flow (ttm)-8.7M